Contacts
Address
Australia, Victoria , Notting Hill, 3168, 10/585 Blackburn Road
Director
Руководитель
Phones of enterprise
management
+61
When placing an order please inform the manager that you've learned the information on Allbiz! Thank you that you buy on Allbiz!
+61
When placing an order please inform the manager that you've learned the information on Allbiz! Thank you that you buy on Allbiz!
Internet
Site:
About enterprise
Biota Holdings, Limited
Biota is a leading anti-infective drug development company based in MelbourneAustralia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir®, is approved for marketing in Japan.
In stock
Inavir® is the first drug of a new class of long acting neuraminidase inhibitors (LANIs) to address the limitation of the current products, which require daily or more frequent dosing. The new class provides the opportunity to medicate patients on a "one and done" basis and offers a number of...
Group: Pharmaceutical Medicines
In stock
Biota's
human rhinovirus (HRV) drug for the prevention and treatment of one of the major causes of the common cold, BTA798, has completed Phase I and Phase IIa clinical trials. Biota is prepared to accept early expressions of interest from partners interested in this program.
Group: Pharmaceutical Medicines
In stock
Relenza™ is GlaxoSmithKline's brand of zanamivir, a first in-class antiviral drug for the treatment and prevention of influenza. Zanamivir was licensed to GlaxoSmithKline by Biota in 1990 and launched worldwide in 1999.
Relenza is delivered directly to the primary site of infection on the lungs,...
Group: Pharmaceutical Medicines
The Centre of Disease Control (CDC) estimates that in the United States alone 4.1 million (1.6) have been infected with HCV. Of these people, 3.2 million are chronically infected. 70% of chronically infected patients progress to chronic liver disease. 1-5% of infected patients die as a result of...
Group: Services of medical research institutes
Gram-positive and Gram-negative bacteria are common causes of serious diseases such as pneumonia and complicated skin infections. The incidence of resistance to currently available antibiotics is increasing and presents an urgent medical need. For example, it is estimated that more than 70 of cases...
Group: Services of medical research institutes
BioStar® OIA® FLU and Biostar® OIA® FLU A/B are two point of care influenza diagnostic kits, manufactured and marketed by Biota's U.S. based commercialisation partner Inverness Medical, as part of their BioStar® product range.
Group: Services of medical research institutes
